De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Elite Pharmaceuticals Inkomsten in het verleden
Verleden criteriumcontroles 5/6
Elite Pharmaceuticals has been growing earnings at an average annual rate of 57.1%, while the Pharmaceuticals industry saw earnings declining at 0.4% annually. Revenues have been growing at an average rate of 27.2% per year. Elite Pharmaceuticals's return on equity is 33.6%, and it has net margins of 29.5%.
Belangrijke informatie
57.1%
Groei van de winst
57.1%
Groei van de winst per aandeel
Pharmaceuticals Groei van de industrie | 6.0% |
Inkomstengroei | 27.2% |
Rendement op eigen vermogen | 33.6% |
Nettomarge | 29.5% |
Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Elite Pharmaceuticals geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 66 | 20 | 8 | 8 |
31 Mar 24 | 57 | 20 | 7 | 7 |
31 Dec 23 | 47 | 16 | 6 | 8 |
30 Sep 23 | 41 | 18 | 5 | 8 |
30 Jun 23 | 35 | 4 | 5 | 6 |
31 Mar 23 | 34 | 4 | 5 | 6 |
31 Dec 22 | 33 | 7 | 6 | 5 |
30 Sep 22 | 33 | 7 | 5 | 4 |
30 Jun 22 | 33 | 7 | 5 | 4 |
31 Mar 22 | 32 | 9 | 4 | 4 |
31 Dec 21 | 29 | 6 | 4 | 5 |
30 Sep 21 | 26 | 6 | 4 | 5 |
30 Jun 21 | 25 | 6 | 4 | 5 |
31 Mar 21 | 25 | 5 | 3 | 5 |
31 Dec 20 | 26 | 7 | 4 | 6 |
30 Sep 20 | 25 | 3 | 4 | 6 |
30 Jun 20 | 22 | -1 | 4 | 5 |
31 Mar 20 | 18 | -2 | 3 | 6 |
31 Dec 19 | 14 | -6 | 3 | 4 |
30 Sep 19 | 12 | -6 | 3 | 6 |
30 Jun 19 | 9 | -7 | 3 | 8 |
31 Mar 19 | 8 | -9 | 3 | 8 |
31 Dec 18 | 8 | -9 | 3 | 9 |
30 Sep 18 | 8 | -8 | 3 | 9 |
30 Jun 18 | 8 | -3 | 3 | 9 |
31 Mar 18 | 7 | -4 | 3 | 10 |
31 Dec 17 | 7 | -4 | 2 | 10 |
30 Sep 17 | 7 | -2 | 3 | 10 |
30 Jun 17 | 8 | 23 | 3 | 9 |
31 Mar 17 | 10 | 25 | 2 | 8 |
31 Dec 16 | 13 | 50 | 3 | 7 |
30 Sep 16 | 13 | 12 | 3 | 9 |
30 Jun 16 | 14 | -22 | 3 | 12 |
31 Mar 16 | 12 | -10 | 3 | 12 |
31 Dec 15 | 9 | -42 | 3 | 15 |
30 Sep 15 | 8 | 16 | 3 | 14 |
30 Jun 15 | 6 | 44 | 3 | 13 |
31 Mar 15 | 5 | 29 | 3 | 15 |
31 Dec 14 | 5 | -49 | 3 | 11 |
30 Sep 14 | 5 | -71 | 3 | 10 |
30 Jun 14 | 5 | -102 | 2 | 7 |
31 Mar 14 | 5 | -97 | 2 | 4 |
31 Dec 13 | 5 | -8 | 2 | 3 |
Kwaliteitswinsten: ELTP has a high level of non-cash earnings.
Groeiende winstmarge: ELTP's current net profit margins (29.5%) are higher than last year (12.4%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: ELTP has become profitable over the past 5 years, growing earnings by 57.1% per year.
Versnelling van de groei: ELTP's earnings growth over the past year (345.3%) exceeds its 5-year average (57.1% per year).
Winst versus industrie: ELTP earnings growth over the past year (345.3%) exceeded the Pharmaceuticals industry 13%.
Rendement op eigen vermogen
Hoge ROE: ELTP's Return on Equity (33.6%) is considered high.